CA125- and tumor-specific T-cell responses correlate with prolonged survival in oregovomab-treated recurrent ovarian cancer patients
- 1 August 2004
- journal article
- clinical trial
- Published by Elsevier in Gynecologic Oncology
- Vol. 94 (2) , 340-351
- https://doi.org/10.1016/j.ygyno.2004.04.024
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Randomized, Placebo-Controlled Study of Oregovomab for Consolidation of Clinical Remission in Patients With Advanced Ovarian CancerJournal of Clinical Oncology, 2004
- Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancerAmerican Journal of Obstetrics and Gynecology, 2003
- OregovomabAmerican Journal of Cancer, 2003
- Recurrent Ovarian Cancer: Evidence-Based TreatmentJournal of Clinical Oncology, 2002
- Ovarian cancer antigen CA125 is encoded by the MUC16 mucin geneInternational Journal of Cancer, 2002
- The CA 125 Gene: A Newly Discovered Extension of the Glycosylated N-Terminal Domain Doubles the Size of This Extracellular SuperstructureTumor Biology, 2002
- Induction of CA125-Specific B and T Cell Responses in Patients Injected with MAb-B43.13—Evidence for Antibody-Mediated Antigen-Processing and Presentation of CA125 in VivoCancer Biotherapy & Radiopharmaceuticals, 2001
- The CA 125 Gene: An Extracellular Superstructure Dominated by Repeat SequencesTumor Biology, 2001
- Anti-idiotype induction therapy: anti-CA125 antibodies (Ab 3 ) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab 1 )Cancer Immunology, Immunotherapy, 1998
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983